# iOmx Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/iomx-therapeutics

- Industry: Biotechnology
- Headquarters: Munich, Germany
- Website: www.iomx.de
- Total disclosed funding: $120M
- Latest round: Series B (Oct 5, 2021)
- Investors on record: 6

## About

iOmx Therapeutics AG is a biotechnology company specializing in targeted cancer immunotherapy treatments, focusing on innovative solutions for solid tumors through the interplay of tumor and myeloid biology.iOmx Therapeutics AG, founded in 2016 and headquartered in Munich, Germany, develops targeted cancer therapies. The company has pivoted toward advancing its drug pipeline and has successfully raised EUR 65.00 mn in SERIES B funding on October 5, 2021. The funding was co-led by new investors Athos Service and MIG Verwaltungs AG. The CEO is Apollon Papadimitriou, and the founder is Nisit Khandelwal.iOmx Therapeutics specializes in the development of targeted cancer immunotherapy treatments, focusing on the interplay between tumor and myeloid biology to create innovative therapeutic solutions for prevalent solid tumors. The company’s core offerings include a pipeline of biomarker-enabled drug programs aimed at addressing immune evasion mechanisms that allow tumors to proliferate. These therapies are designed to operate as single-agent treatments, potentially serving as backbone therapies within various cancer treatment regimens. iOmx targets a global market, implementing its solutions in regions where advanced cancer treatment protocols are established, including North America and Europe. The company’s client base encompasses healthcare providers, oncology specialists, and research institutions actively seeking novel cancer therapies to enhance patient outcomes.iOmx Therapeutics generates revenue primarily through strategic partnerships and collaborations with pharmaceutical companies and research institutions focused on oncology. The transactional structure typically involves co-development agreements that may include milestone payments tied to clinical trial progress, as well as potential royalties on future product sales. These arrangements foster collaborative efforts to expedite the development and commercialization of iOmx's innovative therapies. Revenue is further supplemented through grants and funding from venture capital investors, which support the company's ongoing research initiatives. The specific financial arrangements and pricing plans for individual products or services are structured to align with the value provided to healthcare professionals and institutions that benefit from enhanced cancer treatment options.Following the recent SERIES B funding round of EUR 65.00 mn, iOmx Therapeutics AG plans to advance its lead program IMT-07, a SIK3 kinase inhibitor aimed at treating solid tumors, and to develop IMT-18, a first-in-class monoclonal antibody targeting IGSF11 for PD-1/PD-L1-resistant tumors. The funding will also support the advancement of additional novel immune checkpoint programs to lead candidate stage.

## Funding rounds

- Series B, Oct 5, 2021, $75M — Sofinnova Partners, Wellington Partners, M Ventures, MIG Capital, Athos Service
- Series A, Jul 13, 2016, $44M — Sofinnova Partners, Wellington Partners, MPM BioImpact, M Ventures

## Investors

- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series A, Series B
- Wellington Partners (https://capitalatlas.ai/funds/wellington-partners) — Series A, Series B
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series A
- M Ventures (https://capitalatlas.ai/funds/m-ventures) — Series A, Series B
- MIG Capital (https://capitalatlas.ai/funds/mig-capital) — Series B
- Athos Service — Series B